Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2013 -





Published: November 2013 | Pages: 64 | Format: PDF

 Summary 

 Global Markets Direct’s, 'Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS). Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

 

  •  A snapshot of the global therapeutic scenario for Secondary Progressive Multiple Sclerosis (SPMS). 
  •  A review of the Secondary Progressive Multiple Sclerosis (SPMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  •  Coverage of products based on various stages of development ranging from discovery till registration stages. 
  •  A feature on pipeline projects on the basis of monotherapy and combined therapeutics. 
  •  Coverage of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline on the basis of route of administration and molecule type. 
  •  Key discontinued pipeline projects. 
  •  Latest news and deals relating to the products. 

 

 Reasons to buy 

 

  •  Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS). 
  •  Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  •  Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. 
  •  Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics. 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. 

 

 Additional Information 

 Companies Mentioned 

 

  •  Biogen Idec Inc. 
  •  Novartis AG 
  •  Opexa Therapeutics, Inc. 
  •  Innate Therapeutics Limited 
  •  AB Science 
  •  Daval International Ltd. 

 

 Country 

 Global 

 Introduction 

 Global Markets Direct Report Coverage 

 Secondary Progressive Multiple Sclerosis (SPMS) Overview 

 Therapeutics Development 

 An Overview of Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) 

 Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics under Development by Companies 

 Late Stage Products 

 Comparative Analysis 

 Mid Clinical Stage Products 

 Comparative Analysis 

 Pre-Clinical Stage Products 

 Comparative Analysis 

 Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics - Products under Development by Companies 

 Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics - Products under Investigation by Universities/Institutes 

 Companies Involved in Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Development 

 Biogen Idec Inc. 

 Novartis AG 

 Opexa Therapeutics, Inc. 

 Innate Therapeutics Limited 

 AB Science 

 Daval International Ltd. 

 Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics Assessment 

 Assessment by Monotherapy Products 

 Assessment by Route of Administration 

 Assessment by Molecule Type 

 Drug Profiles 

 siponimod - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 natalizumab - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 imilecleucel-t - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 Lipoic Acid - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 masitinib - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 Epigallocatechin Gallate - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 rituximab - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 Aimspro - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 MIS-416 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 interferon beta-1b biosimilar - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics - Drug Profile Updates 

 Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics - Discontinued Products 

 Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics - Dormant Products 

 Secondary Progressive Multiple Sclerosis (SPMS) - Product Development Milestones 

 Featured News & Press Releases 

 Nov 13, 2012: Opexa Receives Clinical Trial Approval From Health Canada For New T-Cell Therapy, Tcelna 

 Sep 12, 2012: Opexa Initiates Phase IIb Clinical Trial Of Tcelna In Patients With Secondary Progressive Multiple Sclerosis 

 Aug 23, 2012: Novartis In Partnership With Health Canada To Introduce Revised Product Monograph For Gilenya 

 May 21, 2012: Opexa Announces Tcelna As New Brand Name For MS Therapy 

 Appendix 

 Methodology 

 Coverage 

 Secondary Research 

 Primary Research 

 Expert Panel Validation 

 Contact Us 

 Disclaimer 

 List of Tables 

 Number of Products Under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2013 

 Products under Development for Secondary Progressive Multiple Sclerosis (SPMS) - Comparative Analysis, H2 2013 

 Number of Products under Development by Companies, H2 2013 

 Comparative Analysis by Late Stage Development, H2 2013 

 Comparative Analysis by Mid Clinical Stage Development, H2 2013 

 Comparative Analysis by Pre-Clinical Stage Development, H2 2013 

 Products under Development by Companies, H2 2013 

 Products under Investigation by Universities/Institutes, H2 2013 

 Biogen Idec Inc., H2 2013 

 Novartis AG, H2 2013 

 Opexa Therapeutics, Inc., H2 2013 

 Innate Therapeutics Limited, H2 2013 

 AB Science, H2 2013 

 Daval International Ltd., H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013 

 Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics - Drug Profile Updates 

 Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics - Discontinued Products 

 Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics - Dormant Products 

 List of Figures 

 Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2013 

 Products under Development for Secondary Progressive Multiple Sclerosis (SPMS) - Comparative Analysis, H2 2013 

 Products under Development by Companies, H2 2013 

 Late Stage Products, H2 2013 

 Mid Clinical Stage Products, H2 2013 

 Pre-Clinical Stage Products, H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Route of Administration, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Molecule Type, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013